NCT01134666 2017-06-09An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal CancerMerck KGaA, Darmstadt, GermanyTerminated165 enrolled